search icon
Join IDSAJOIN IDSA >> Go to MyIDSAGO TO MYIDSA >>
  • What's New in Practice Management & Payment

    CMS: New Quality Payment Program Resources Available

    CMS will be hosting a webinar on Physician Compare

    MIPS 2017: Important Dates & Information

    New CPT® Modifier for Telemedicine Services

  • Upcoming Meetings

    IDWeek 2017 logo
    April 23 - 28, 2017 | Boston, MA

    Infectious Diseases in Adults 2017

    May 11 - 12, 2017 | New York City, New York

    HIV and Hepatitis Management: The New York Course

  • Find Practice Guidelines

    Also available:

  • Read the Latest from Science Speaks: Global ID News


  • Project’s goal: End malaria for all

    Community-based and comprehensive, response to HIV among people injecting drugs in Athens reversed climb in new cases

    Mark Wainberg, 1945-2017

  • Policy News

    3/31/2017

    IDSA Leads Support for READI Act (PDF)

    IDSA and over forty other organizations representing healthcare providers, hospitals, pharmacists, scientists and microbiologists, industry, public health experts, patients and advocates expressed support for the Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act.

  • Breaking News and Alerts

    4/10/2017 12:24:52 PM

    FDA approves two hepatitis C drugs for pediatric patients

    The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults.

    4/4/2017 3:21:04 PM

    CDC: About 1 in 10 U.S. pregnant women with confirmed Zika infection had a fetus or baby with birth defects in 2016

    Of the 250 pregnant women who had confirmed Zika infection in 2016, 24 – or about 1 in 10 of them – had a fetus or baby with Zika-related birth defects, according to a new Vital Signs report from the Centers for Disease Control and Prevention (CDC). This report is the first to provide the analysis of a subgroup of pregnant women in the U.S. with clear, confirmed test results of Zika virus infection.

    3/27/2017 12:24:20 PM

    CDC Updates Specimen Collection, Shipping, and Testing Guidance for Suspected Acute Flaccid Myelitis (AFM) Cases

    Despite extensive pathogen-specific testing of many specimens since 2014, CDC and others have not identified an etiology for the AFM cases. Therefore, CDC will no longer perform clinical diagnostics for enteroviruses or metagenomic sequencing on specimens collected from suspect cases of AFM.

    3/27/2017 12:10:57 PM

    Information for Healthcare Personnel Potentially Exposed to Hepatitis C Virus (HCV): Recommended Testing and Follow-up

    Exposure to viral hepatitis has long been recognized as an occupational risk for healthcare personnel, with recommendations previously established for the management of occupational exposures to hepatitis C virus (HCV). 

    3/10/2017 12:01:56 PM

    CDC adds 4 countries to interim travel guidance related to Zika virus

    CDC is working with other public health officials to monitor for ongoing spread of Zika virus‎. Today, CDC posted a Zika virus travel notice for Angola, Guinea-Bissau, Maldives and Solomon Islands. . 

    2/2/2017 3:52:05 PM

    New FDA Drug Safety Communication on chlorhexidine gluconate - Drug Information Update

    New FDA Drug Safety Communication on chlorhexidine gluconate- Drug Information Update

    1/17/2017 5:07:35 PM

    FDA MedWatch - ED-3490TK Video Duodenoscope by Pentax: FDA Safety Communication - UPDATE

    FDA Alert

    1/17/2017 4:24:11 PM

    FDA MedWatch - Duodenoscopes by Fujifilm Medical Systems: Safety Communication - Certain Older Models Removed From Clinical Use

    FDA Alert

  • News from IDSA and the Journals

    Tax Credit Bill Introduced

    Read More >>

    IDSA strongly supports the Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act, H.R. 1840, introduced yesterday by Representatives Erik Paulsen (R-MN) and Mike Thompson (D-CA), which would provide a new tax credit, modeled after the Orphan Drug tax credit, for new antibiotics that treat a serious or life threatening infection and address an unmet medical need and for new rapid diagnostic tests.

| HIVMA | Contact Us

© Copyright IDSA 2017 Infectious Diseases Society of America

Full Site Mobile Site